QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 d-boral-capital-maintains-buy-on-cytosorbents-maintains-10-price-target

D. Boral Capital analyst Jason Kolbert maintains CytoSorbents (NASDAQ:CTSO) with a Buy and maintains $10 price target.

 cytosorbents-to-refile-de-novo-application-for-drugsorb-atr-expects-fda-review-in-mid-2026

 CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit an...

 d-boral-capital-maintains-buy-on-cytosorbents-maintains-10-price-target

D. Boral Capital analyst Jason Kolbert maintains CytoSorbents (NASDAQ:CTSO) with a Buy and maintains $10 price target.

 d-boral-capital-maintains-buy-on-cytosorbents-maintains-10-price-target

D. Boral Capital analyst Jason Kolbert maintains CytoSorbents (NASDAQ:CTSO) with a Buy and maintains $10 price target.

 cytosorbents-q2-adj-eps-005-inline-sales-962m-miss-980m-estimate

CytoSorbents (NASDAQ:CTSO) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 3...

 d-boral-capital-maintains-buy-on-cytosorbents-maintains-10-price-target

D. Boral Capital analyst Jason Kolbert maintains CytoSorbents (NASDAQ:CTSO) with a Buy and maintains $10 price target.

 d-boral-capital-maintains-buy-on-cytosorbents-maintains-10-price-target

D. Boral Capital analyst Jason Kolbert maintains CytoSorbents (NASDAQ:CTSO) with a Buy and maintains $10 price target.

 cytosorbents-files-request-for-supervisory-review-with-fda-of-de-novo-denial-letter-issued-for-cytosorbents-drugsorb-atr-device

CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and...

 cytosorbents-presents-real-world-analysis-at-europcr-2025-showing-reduction-in-severe-bleeding-and-transfusion-needs-in-cabg-patients-on-blood-thinner-ticagrelor-with-cytosorbents-therapy

Real-World Analysis Shows Statistically Significant Reduction in Severe Bleeding and Transfusion Needs in CABG Patients on the ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION